Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Annovis Bio, Inc. before investing.

In this article, we go over a few key elements for understanding Annovis Bio, Inc.’s stock price such as:

• Annovis Bio, Inc.’s current stock price and volume
• Why Annovis Bio, Inc.’s stock price changed recently
• Upgrades and downgrades for ANVS from analysts
• ANVS’s stock price momentum as measured by its relative strength

About Annovis Bio, Inc. (ANVS)

Before we jump into Annovis Bio, Inc.’s stock price, history, target price and what caused it to recently rise, let’s take a look at some background.

Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company’s lead product candidate is Buntanetap, which is in phase 3 to treat alzheimer’s disease, as well as in open-label phase 3 to treat parkinson’s disease. It also develops ANVS405, which is in phase 2 and 3 clinical trials for the treatment of traumatic brain injury and/or stroke; and ANVS301, which finished phase 1 clinical trial developed to increase cognitive capability in later stages of alzheimer’s disease and dementia. Annovis Bio, Inc. was incorporated in 2008 and is headquartered in Malvern, Pennsylvania.

Want to learn more about Annovis Bio, Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Annovis Bio, Inc..

Annovis Bio, Inc.’s Stock Price as of Market Close

As of August 21, 2026, 4:00 PM, CST, Annovis Bio, Inc.’s stock price was $1.820.

Annovis Bio, Inc. is up 1.68% from its previous closing price of $1.790.

During the last market session, Annovis Bio, Inc.’s stock traded between $1.770 and $1.840. Currently, there are approximately 27.85 million shares outstanding for Annovis Bio, Inc..

Annovis Bio, Inc.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

Annovis Bio, Inc. Stock Price History

Annovis Bio, Inc.’s (ANVS) price is currently up 4% so far this month.

During the month of August, Annovis Bio, Inc.’s stock price has reached a high of $1.980 and a low of $1.710.

Over the last year, Annovis Bio, Inc. has hit prices as high as $5.500 and as low as $1.541. Year to date, Annovis Bio, Inc.’s stock is down 47.4%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Annovis Bio, Inc. Stock’s Price to Rise?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of August 21, 2026, there was 1 analyst who downgraded Annovis Bio, Inc.’s stock and 0 analysts who upgraded over the last month.

Additionally, you'll want to evaluate Annovis Bio, Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Annovis Bio, Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Annovis Bio, Inc. (ANVS) by visiting AAII Stock Evaluator.

Relative Price Strength of Annovis Bio, Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of August 21, 2026, Annovis Bio, Inc. has a weighted four-quarter relative price strength of -10.20%, which translates to a Momentum Score of 21 and is considered to be Weak.

Want to learn more about how Annovis Bio, Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Annovis Bio, Inc. Stock Price: Bottom Line

As of August 21, 2026, Annovis Bio, Inc.’s stock price is $1.820, which is up 1.68% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Annovis Bio, Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.